Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib. Patients with chronic myelogenous leukemia (CML ...

Initial discussions about treatment, side effects and study results can help patients navigate through all aspects of a chronic myeloid leukemia diagnosis. The initial discussions with health care ...

The life expectancy of patients with recently diagnosed chronic myeloid leukemia (CML) is now approaching that of the general population, which is an important message for physicians to convey to ...

The case is believed to be just the second reported in the scientific literature. In patients with chronic myelogenous leukemia (CML), patients sometimes present with soft-tissue hematomas resulting ...

New year, new authors are visiting the Columbus Metropolitan Library (CML). After introducing the revamped Authors at the ...

An advocate discusses vital patient-provider conversations to promote the best care for individuals with chronic myeloid leukemia. Receiving a diagnosis of chronic myeloid leukemia (CML) can be ...

Please provide your email address to receive an email when new articles are posted on . It has been eight years since imatinib was approved as the first oral tyrosine kinase inhibitor indicated for ...

LONDON--(BUSINESS WIRE)--The global chronic myelogenous leukemia (CML) therapeutics market size is poised to grow by USD 1.74 billion during 2019-2023, according to a new report by Technavio, ...